Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis.

Détails

ID Serval
serval:BIB_CC7BAF315FEA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis.
Périodique
Blood pressure
Auteur⸱e⸱s
Burnier M., Lin S., Ruilope L., Bader G., Durg S., Brunel P.
ISSN
1651-1999 (Electronic)
ISSN-L
0803-7051
Statut éditorial
Publié
Date de publication
12/2019
Peer-reviewed
Oui
Volume
28
Numéro
6
Pages
358-374
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis ; Systematic Review
Publication Status: ppublish
Résumé
Objective: Angiotensin receptor blockers (ARB) are among the recommended first-line treatment options in patients with hypertension and chronic kidney disease (CKD). This meta-analysis evaluated the effect of ARB on blood pressure (BP) and renal function in patients with concomitant hypertension and CKD with or without diabetes.Methods: Literature search was performed in PubMed/MEDLINE, EMBASE and BIOSIS to identify parallel-group, randomized controlled trials (≥8 weeks) reporting the effects of ARB on office systolic/diastolic BP (SBP/DBP), estimated glomerular filtration rate (eGFR), serum creatinine (SCr), creatinine clearance (CrCl) or proteinuria in adults with hypertension and CKD. Mean difference (MD, generic inverse variance) with 95% confidence intervals (CIs) was used to report an outcome.Results: Among the 24 studies identified, 19 evaluated ARB as monotherapy, 4 evaluated ARB as combination therapy and one evaluated ARB both as monotherapy and combination therapy. Median (range) duration of the studies was 12 (1.84-54.0) months. ARB monotherapy significantly (p < 0.01) reduced BP (treatment ≥1 year: SBP [MD: -14.84 mmHg; 95% CI: -17.82 to -11.85]/DBP [-10.27 mmHg; -12.26 to -8.27]) and proteinuria (≥1 year [-0.90 g/L; -1.22 to -0.59]). Results were consistent for combination therapy. In these studies, non-significant changes were observed for eGFR, CrCl and SCr. The impact of SBP changes on eGFR was not significant; however, studies were of a relatively short duration.Conclusion: ARB had a favorable impact on BP and renal parameters such as proteinuria with monotherapy as well as with combination therapy, highlighting their potential benefits in patients with hypertension and CKD. During the short follow-up of these studies, no significant change in eGFR was observed.
Mots-clé
Angiotensin Receptor Antagonists/pharmacology, Blood Pressure/drug effects, Glomerular Filtration Rate, Humans, Hypertension/complications, Hypertension/drug therapy, Kidney/drug effects, Kidney/physiology, Kidney Failure, Chronic/complications, Kidney Failure, Chronic/drug therapy, Randomized Controlled Trials as Topic, Angiotensin receptor blocker, chronic kidney disease, creatinine clearance, hypertension, proteinuria
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/08/2019 21:05
Dernière modification de la notice
16/02/2021 6:27
Données d'usage